Full-Time

Senior Device Technical Regulatory Specialist

Updated on 7/22/2026

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Dublin, Ireland

In Person

On-site role in Dublin, Ireland.

Category
Legal & Compliance (1)

Get referred to Viatris

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in a scientific/engineering discipline
  • Masters or higher degree desirable
  • Broad experience in the Medical Device and/or Drug-Device Combination Product industry
  • Knowledge and demonstrable experience of global Medical Device and Drug-Device Combination Product regulatory requirements and regulatory planning including but not limited to 21 CFR 820 and MDR (EU) 2017/745
  • Knowledge and demonstrable experience of global Medical Device and Drug-Device Combination Product quality requirements including but not limited to device design controls in accordance with ISO 13485 and 21 CFR 820.10(c)
  • Demonstrable experience in multi-disciplinary teams within a pharmaceutical development environment, with a significant proportion having a drug delivery/device focus
  • Experience, at a team level, in device development programs, specifically with a focus on the preparation and delivery of device technical regulatory submission content
  • Demonstrable track record of competence in leading device program teams in problem solving approaches to device technical regulatory issues
  • Excellent communicator; clear and concise in communications, both written and verbal
  • Strong team player that is willing to take on and support other activities outside core expertise as required to develop the future of the department
  • Proficiency in speaking, comprehending, reading and writing English
Responsibilities
  • Actively collaborate within both the Device Technical Regulatory function and wider Global Device Development (GDD) on the development of regulatory strategies for combination products and medical devices
  • Lead the Device Program Teams (DPTs) in the implementation and execution of strategies and plans that ensure compliance to regulations, legislations, regulatory guidelines and standards
  • Lead the DPTs in their awareness of current regulatory best practice when building device development plans
  • Collaborate within DPTs to generate regulatory plans (for example, for meeting requests and submissions) which are aligned with the overall program level timelines
  • Collaborate within DPTs to ensure regulatory strategies are disseminated and understood and aligned with the key milestones and critical path activities of the program
  • Author and review (and drive the authoring and review) of documents for regulatory submissions; including, but not limited to, New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), Biologics License Application (BLA), Marketing Authorisation Applications (MAAs), Notified Body Opinion (NBOp) applications, variations and other related activities (e.g. meeting requests and planning and execution)
  • Ensure timely feedback to GDD Management Team (MT) and DPT on the outcomes of meeting / agency feedback with consideration to program and portfolio level consequences
  • Actively support the learning and development of the Device Technical Regulatory team

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA acceptance of meloxicam NDA on May 18, 2026 with PDUFA decision December 27, 2026.
  • Greater China revenue 9.8% growth in Q1 2026 driven by cardiovascular demand and e-commerce investments.
  • New product revenues $71 million in Q1 2026 from launches including XULANE LO and meloxicam pipeline.

What critics are saying

  • EpiPen market exclusivity loss late 2026 slashes $1.2B annual revenue with 40–50% margin erosion.
  • Indore facility FDA reinspection delay beyond Q1 2027 halts $900M capacity risking $120M quarterly loss.
  • Negative ROIC of –2.6% versus 8.2% WACC destroys $1.1B shareholder value annually with no recovery moat.

What makes Viatris unique

  • Unique first approved GAD treatment Effexor SR in Japan with 7.6% patient prevalence.
  • Only global portfolio combining branded drugs, generics, complex generics, biosimilars across 165 countries.
  • Fast acting meloxicam candidate targeting 80 million acute pain patients as non-opioid alternative in US.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.